{"title":"A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report","authors":"R. Seljelid, J. Bøgwald","doi":"10.47733/gjccr.2021.2204","DOIUrl":null,"url":null,"abstract":"A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 μg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Journal of Cancer Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47733/gjccr.2021.2204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 μg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
